What are 351(A) & 351(K)?

The FDA is a federal agency of the United States Department of Health and Human Services, tasked with protecting public health by ensuring the safety, efficacy, and security of human and veterinary drugs, biological products, and medical devices. The regulation of biological products is particularly complex due to the products' sources from living organisms and their unique properties.

Section 351(a) Biologics

Section 351(a) of the PHSA pertains to the licensure of biological products based on a full and independent demonstration of safety, purity, and potency. This pathway is typically used for original biologics, including vaccines, blood and blood products, cellular and gene therapies, and tissues.

What is the importance and role of 351(A) biopharmaceuticals?

The 351(a) pathway ensures that new biologics meet stringent standards before they can be marketed. It requires comprehensive data from preclinical and clinical trials to demonstrate that a product is safe and effective for its intended use.

Approval Process 351(a) in pathway.

The approval process under 351(a) involves several steps, including pre-IND (Investigational New Drug) meetings, IND applications, clinical trials (Phase 1-3), Biologics License Application (BLA) submission, and FDA review. The FDA also inspects manufacturing facilities to ensure compliance with Good Manufacturing Practices (GMP).

Section 351(k) Biologics

Section 351(k) of the PHSA provides a pathway for the approval of biosimilars, which are biological products that are highly similar to an already FDA-approved biological product, known as the reference product. Biosimilars must have no clinically meaningful differences in terms of safety, purity, and potency from the reference product.

What is the importance and role of 351(K) biopharmaceuticals?

The 351(k) pathway is crucial for promoting competition in the biologics market, potentially reducing healthcare costs. It allows manufacturers to rely on existing scientific knowledge about the safety and effectiveness of the reference product, thereby reducing the need for extensive and costly clinical trials.

Approval Process 351(K)

For a biosimilar to be approved under 351(k), the applicant must demonstrate bio similarity to the reference product through analytical studies, animal studies, and a clinical study or studies. The process includes an evaluation of the biosimilar's pharmacokinetics, pharmacodynamics, immunogenicity, and, if necessary, clinical efficacy and safety.

Difference between 351(a) and 351(k) in Pathway

The main difference between the two pathways lies in their purpose and requirements. Section 351(a) is for the approval of new, original biological products, requiring extensive data to demonstrate safety and efficacy. In contrast, Section 351(k) is for the approval of biosimilars, where the emphasis is on demonstrating bio similarity to an already approved product, thereby requiring less clinical data.


Sections 351(a) and 351(k) of the PHSA play vital roles in the regulatory framework of biological products in the United States. While 351(a) focuses on the introduction of new biologics, ensuring they meet high standards for safety, purity, and potency, 351(k) facilitates the entry of biosimilars into the market, promoting competition and potential cost savings. Both pathways underscore the FDA's commitment to public health by ensuring that biological products are both effective and safe for consumer use.

How can we help you?
Call us on:+1 (302) 601-2755
Contact our experts today !